about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

5 years ago
Pharma
FDA+

EMA re­moves neg­a­tive note on la­bel of PTC's Duchenne drug; GSK, Ake­bia win Japan OK for oral ane­mia drugs

5 years ago
News Briefing

Phar­ma gi­ants re­turn to an­tibi­otics hud­dle to launch $1B ven­ture fund — re­port

5 years ago
Financing

Sekar Kathire­san show­cas­es his­toric mon­key da­ta in hunt for a once-and-done gene edit­ing ap­proach to pre­vent heart ...

5 years ago
Discovery
Cell/Gene Tx

Pre­sent­ed with up­beat Alzheimer's ag­i­ta­tion da­ta, FDA sees an­oth­er 'break­through' in Ax­some's AXS-05

5 years ago
R&D
FDA+

Ab­b­Vie’s first post-merg­er Al­ler­gan drug pitch strikes out with the FDA as reg­u­la­tors turn thumbs down on Lu­cen­tis ...

5 years ago
FDA+

Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M ...

5 years ago
Coronavirus

Take­da joins mi­cro­bio­me-fo­cused biotech part­ner's $52.6M raise as it pur­sues more in-house can­cer work

5 years ago
Financing

Back to the im­munol­o­gy draw­ing board, Ab­b­Vie inks dis­cov­ery deal with old Al­ler­gan part­ner

5 years ago
Deals
Discovery

Covid-19 roundup: An­tho­ny Fau­ci, Stephen Hahn tes­ti­fy in Con­gress; Chi­na's Sinopharm speeds in­to PhI­II vac­cine tri­al

5 years ago
Coronavirus

Is it re­al­ly over? La Jol­la signs ac­qui­si­tion with Tetraphase af­ter out­bid­ding Acel­Rx, Melin­ta

5 years ago
Deals

FDA lifts par­tial hold on can­cer drug af­ter In­nate re­solves man­u­fac­tur­ing is­sue

5 years ago
FDA+

Bet­ter than Eylea, as durable as gene ther­a­py? Per­cep­tive, Xon­toge­ny boost oph­thalmic star­tup's shot for best of all ...

5 years ago
Financing
Startups

Boehringer In­gel­heim to cash out Hik­ma stake; Breast can­cer biotech sets terms for IPO

5 years ago
News Briefing

Sev­en years af­ter li­cens­ing BTK in­hibitor from Bio­gen, be­lea­guered pen­ny­s­tock biotech part­ner con­cedes de­feat

5 years ago
R&D

Meet the lat­est ge­nom­ic da­ta com­pa­ny — aka WuXi NextCODE with­out the Chi­na op­er­a­tions

5 years ago
China
Outsourcing

What's the hard cost of a piv­otal drug tri­al? A lot less than you might ex­pect

5 years ago
Pharma

Sarep­ta ex­pands gene ther­a­py toolk­it, bets $72.5M to hitch a ride on Co­di­ak's ex­o­some tech

5 years ago
Deals
Cell/Gene Tx

Trans-At­lantic VC banks $126M to scout start­up ideas out of 'un­der­ven­tured' ar­eas in the UK

5 years ago
Financing

Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

5 years ago
Financing
R&D

Covid-19 roundup: One Chi­nese biotech en­ters clin­ic, an­oth­er eyes fall com­ple­tion, a third shoots for 2021 — while ...

5 years ago
Coronavirus

Epizyme hits the ground run­ning with sec­ond — and cru­cial — OK for Tazverik, in fol­lic­u­lar lym­phoma

5 years ago
Pharma
FDA+

Nan Fung Life Sci­ences antes up $32M to fu­el a neu­ro play as the Hong Kong con­glom­er­ate burns through $1.5B man­date

5 years ago
Financing
Startups

Covid-19 roundup: Roche's Actem­ra marred by neg­a­tive re­sults; Here comes an­oth­er sin­gle-armed remde­sivir tri­al

5 years ago
Coronavirus
First page Previous page 72737475767778 Next page Last page
A service from the Financial Times